Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Clinical trial NCT06881784 · RECRUITING

Trial details

NCT number: NCT06881784
Sponsor: Revolution Medicines, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung Cancer NSCLC NSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)

Start date: 2025-05-06
Primary completion: 2027-12-01
Enrollment: 590

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.